(Reuters) -Pfizer CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required, as the Trump administration threatens ...

March 3 (Reuters) - Pfizer (PFE.N), opens new tab CEO Albert Bourla said on Monday the drugmaker might move overseas manufacturing to its existing plants in the United States, if required ...

Pfizer logo is seen on Pfizer World Headquarters in Manhattan, New York, United States of America, on July 6th, 2024. - Image: NurPhoto / Contributor (Getty Images) Pfizer made some major changes ...

Conservative commentator Megyn Kelly claimed the Pfizer COVID vaccine left her with an auto-immune disorder in explosive new comments on her latest podcast episode Wednesday. Kelly, 54 ...

Note: This story has been corrected to clarify that Talis Biomedical did not file for bankruptcy in 2024 but is no longer an operating company. We regret the error ...

The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the company announced Monday. Patrizia Cavazzoni was formerly director ...

After leaving the FDA, where she served as director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., is returning to her previous employer: Big Pharma Pfizer. After ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well with its antibody-drug conjugates (ADCs). Ivonescimab remains the ...

It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...

Pfizer's disclosure Friday that it is ending global development and commercialization efforts for its hemophilia B treatment Beqvez brings an inauspicious ending to a gene therapy that got its ...

Summit Therapeutics and Pfizer on Monday said they will test an experimental Summit immunotherapy with Pfizer’s antibody drug conjugates in trials evaluating two of the sector’s most closely watched ...